Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): Clinical implications

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 813-825

  Bui, Khanh ^a   Earley, Willie ^a   Nyberg, Svante ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antipsychotic agents; Bipolar disorder; Dose; Drug safety; Pharmacokinetics; Quetiapine; Response relationship; Schizophrenia

Indexed keywords

QUETIAPINE;

AREA UNDER THE CURVE; BIPOLAR DEPRESSION; CONSTIPATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84878850777     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.794774     Document Type: Review

References (57)

1. AstraZeneca. Seroquel-(quetiapine fumarate) tablets/US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/seroquel.pdf [Last accessed 9 July 2012]
2. AstraZeneca UK Limited. Seroquel Summary of Product Characteristics (UK). Available at: http://www.medicines.org.uk/emc/medicine/2295 [Last accessed 16 November 2012]
3. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22
4. Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18:81-98 (Pubitemid 351311245)
5. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63(Suppl 13):5-11 (Pubitemid 35471364)
6. Reilly-Harrington N, Sachs GS. Psychosocial strategies to improve concordance and adherence in bipolar disorder. J Clin Psychiatry 2006;67:e04
7. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909 (Pubitemid 35231730)
8. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006;67:1542-50 (Pubitemid 44787436)
9. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52 (Pubitemid 47284561)
10. Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011;62:1032-40
11. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8: 232-41
12. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
13. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8 (Pubitemid 43837695)
14. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-15 (Pubitemid 37490235)
15. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12 (Pubitemid 350033432)
16. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl 16):10-13 (Pubitemid 37523322)
17. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23: 637-51 (Pubitemid 27485972)
18. Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007;21:129-41
19. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9 (Pubitemid 14064945)
20. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets-US prescribing information. Available at: http://www1.astrazeneca-us. com/pi/seroquelxr.pdf [Last accessed 25 October 2012]
21. AstraZeneca. Seroquel XR-Summary of Product Characteristics for Ireland. Available at: http://www.medicines.ie/medicine/13032/SPC/Seroquel\+ XR\+ 50mg%2c \+ 150mg%2c \+ 200mg%2c\+300mg%2c\+400mg\+ prolonged-release\+tablets/[Last accessed 18 May 2012]
22. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and activecontrolled study. Int J Neuropsychopharmacol 2010;13:305-20
23. Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011;31:418-28
24. Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25:103-15
25. Ganesan S, Agambaram V, Randeree F, et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24:21-32 (Pubitemid 351160235)
26. Mö ller H-J, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008;23:95-105 (Pubitemid 351317282)
27. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:199-204
28. Juckel G, Winter HR, Sta° hle L, et al. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal. Schizophr Res 2008;98:163-4
29. Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502
30. Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, Phase IV study. Clin Ther 2012;34:2202-11
31. Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediaterelease and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14:1357-66
32. Nyberg S. PET-measured occupancy of the D2 receptor: a comparison of quetiapine fumarate immediate-and extended-release formulations in healthy subjects. Eur Psychiatry 2010;25:300, abs P01-70
33. Sunkara G, Chilikuri DM. IVIVC: an important tool in the development of drug delivery systems. Drug Dev Deliv 2003;3(4) 34.
34. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832-42 (Pubitemid 47015481)
35. Emborg C, Hallerback T, Jorgensen L, et al. A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Hum Psychopharmacol 2012;27:492-8
36. Dell'Osso B, Arici C, Dobrea C, et al. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol 2012;27:310-13
37. Eriksson L, Hallerbä ck T, Jö rgensen L, et al. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized schizophrenic patients-a retrospective study. Ther Adv Psychopharmacol 2012;2:6217-26
38. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
39. Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry 2010;25(Suppl 1):1446, abstract PW01-27
40. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992;33:115-20
41. Cana F. Mechanisms of action of atypical antipsychotics. CNS Spectr 2005;10:5-11
42. Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs-D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-6 (Pubitemid 34655465)
43. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:275-82 (Pubitemid 44959242)
44. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38 (Pubitemid 34302921)
45. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res 2003;3:108-17 (Pubitemid 36975299)
46. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
47. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60 (Pubitemid 40905587)
48. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetinecontrolled study. J Clin Psychiatry 2009;70:526-39
49. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71:163-74
50. Thase M, Macfadden W, McCoy R, et al. Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory double-blind, placebo-controlled study (The BOLDER II Study). Int J Neuropsychopharmacol 2006;9(Suppl 1):S237, abstract P03.035
51. Stahl S. Psychopharmacology of Antidepressants. London, UK: Martin Dunitz Ltd, 2008
52. Goldstein JM, Christoph G, Grimm S, et al. Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol 2007;17(Suppl 4):S401
53. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-9 (Pubitemid 30349435)
54. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69:81-6 (Pubitemid 351282000)
55. Farde L, Mack RJ, Nyberg S, et al. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 1997;12(Suppl 1):S3-7 (Pubitemid 27171183)
56. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-8 (Pubitemid 28307604)
57. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-75 (Pubitemid 29260341)